Je was op zoek naar: egfr (Maltees - Engels)

egfr- mhux
egfr

għall-egfr
mutation-negative

egfr jattiva proteini msejħa ras.
egfr activates proteins called ras.

ta’ egfr [-5.6%, 7.3%]
[-5.6%, 7.3%]

egfr hu involut fl-iżvilupp tal-fetu.
egfr is involved in foetal development.

kuri preċedenti kienu jinkludu egfr tki u kimoterapija.
prior treatments included egfr tki and chemotherapy.

stat ta’ mutazzjoni tal-egfr u karatteristiċi kliniċi
egfr mutation status and clinical characteristics

evalwazzjoni tal-istat ta’ mutazzjoni ta’ egfr
assessment of egfr mutation status

l-egfr kien ikkalkolat permezz tal-ekwazzjoni mdrd4.
the egfr was calculated using the mdrd4 equation.

valutazzjoni tal-istatus ta' mutazzjoni t790m ta' egfr
assessment of egfr t790m mutation status

mutazzjonijiet li jattivaw egfr, l-mah għandu jissottometti dejta matura dwar is
squamous nsclc harbouring egfr activating mutations, the mah should

barra dan, necitumumab in vitro jikkaġuna internalizzazzjoni u degradazzjoni ta’ egfr.
in addition, necitumumab induces egfr internalization and degradation in vitro.

erlotinib jinibixxi b’mod qawwi l-phosphorylation intraċellulari ta’ egfr.
erlotinib potently inhibits the intracellular phosphorylation of egfr.

antikorpi monoklonali għal egfr flimkien ma’ korsijiet ta’ kimoterapija b’bevacizumab
egfr monoclonal antibodies in combination with bevacizumab chemotherapy regimens

fatturi li jbassru l- preżenza ta’ tibdil fiċ-ċelloli ta’ egfr
factors that predicted for presence of egfr mutation

linja addizzjonali ta’ terapija tk1 kienet permessa għal pazjenti b’mutazzjoni egfr jew translokazzjoni alk magħrufa.
an additional line of tki therapy was allowed for patients with known egfr mutation or alk translocation.

it-tumur kien ikkunsidrat li jkun jesprimi egfr jekk ċellula waħda li tkun immarkata tkun tista’ tiġi identifikata.
a tumour was considered to be egfr-expressing, if one stained cell could be identified.

f’ mudelli mhux kliniċi, inibizzjoni ta ’ egfr phosphotyrosine jirriżulta fi stasi ċellolari u/ jew mewt.
in non-clinical models, inhibition of egfr phosphotyrosine results in cell stasis and/ or death.

cetuximab jimblokka t-twaħħil ta’ ligandi egfr endoġeniċi li jfixkel il-funzjoni tar- riċettur.
cetuximab blocks binding of endogenous egfr ligands resulting in inhibition of the function of the receptor.